---
title: "Silexion Therapeutics Corp 1Q 2026: Net loss $2.7M, EPS ($0.85) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286619052.md"
description: "Silexion Therapeutics Corp reported a net loss of $2.7M for Q1 2026, with a loss per share of $0.85, compared to a net loss of $1.7M and $3.84 per share in Q1 2025. The increase in losses is attributed to heightened R&D spending for the clinical start of SIL204, with human studies anticipated in Q2 2026. The company has restored Nasdaq compliance and is utilizing public financings to support operations and clinical milestones."
datetime: "2026-05-15T21:31:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286619052.md)
  - [en](https://longbridge.com/en/news/286619052.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286619052.md)
generator: "portal-rs"
---

# Silexion Therapeutics Corp 1Q 2026: Net loss $2.7M, EPS ($0.85) — 10-Q Summary

Silexion Therapeutics Corp reported a net loss of $2.7M for the first quarter of 2026, with loss per share, basic and diluted of $0.85, compared with a net loss of $1.7M and loss per share of $3.84 in the year‑ago quarter, as the company stepped up spending to support the upcoming clinical start for SIL204 — 10-Q Summary.

**Financial Highlights**

-   Net income: Net loss of $2.7M for 1Q 2026, versus net loss of $1.7M in 1Q 2025.
-   Diluted EPS: Loss per share, basic and diluted $0.85 for 1Q 2026, versus $3.84 for 1Q 2025.

**Business Highlights**

-   Clinical advancement: SIL204 development progressed with preparatory toxicology, GMP manufacturing and trial readiness; human studies expected in Q2 2026.
-   R&D investment shift: R&D spending rose sharply to support clinical start, driven by subcontractors, toxicology and manufacturing work.
-   Capital raising channels: The company transitioned to public financings and ATM sales to fund operations and upcoming clinical milestones.
-   Public listing & compliance: Restored Nasdaq compliance and executed a reverse split and an authorized share increase to support future financings.

Original SEC Filing: Silexion Therapeutics Corp \[ SLXN \] - 10-Q - May. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md)

## Related News & Research

- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers](https://longbridge.com/en/news/295325850.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**